N-acetylcysteine as a treatment for substance use cravings: A meta-analysis DOI Creative Commons
Emma L. Winterlind, Samantha G. Malone, Michael Setzer

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 13, 2024

N-acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and craving in individuals with disorders (SUDs), possibly through its potential to regulate glutamate. Though prior meta-analyses generally support NAC's efficacy reducing symptoms of craving, individual trials have found mixed results. The aims the this updated meta-analysis were (1) examine NAC treating SUD (2) explore subgroup differences, risk bias, publication bias across trials. Database searches PubMed, Cochrane Library, ClinicalTrials.gov conducted June July 2023 identify relevant randomized control (RCTs). consisted 9 which analyzed data from total 623 participants. most targeted clinical was alcohol (3/9; 33.3%), followed by tobacco (2/9; 22.2%) multiple substances 22.2%). Meta-analysis, analyses, leave-one-out analyses treatment effect on adverse events (AEs). Risk assessments, Egger's tests, funnel plot tests bias. did not significantly outperform placebo (SMD = 0.189, 95% CI -0.015 - 0.393). Heterogeneity very high (99.26%), indicating that findings been influenced or methodological differences study protocols. Additionally, results indicate there be present. Overall, our are contrary those meta-analyses, suggesting limited impact craving. However, heterogeneity presence identified warrants cautious interpretation meta-analytic outcomes.

Language: Английский

Identification and external validation of a problem cannabis risk network DOI
Sarah Lichenstein, Brian D. Kiluk, Marc N. Potenza

et al.

Biological Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
N‐acetylcysteine as a treatment for substance use cravings: A meta‐analysis DOI Creative Commons
Emma L. Winterlind, Samantha G. Malone, Michael Setzer

et al.

Addiction Biology, Journal Year: 2024, Volume and Issue: 29(11)

Published: Nov. 1, 2024

Abstract N‐acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and craving in individuals with disorders (SUDs), possibly through its potential to regulate glutamate. Though prior meta‐analyses generally support NAC's efficacy reducing symptoms of craving, individual trials have found mixed results. The aims this updated meta‐analysis were (1) examine the NAC treating SUD (2) explore subgroup differences, risk bias publication across trials. Database searches PubMed, Cochrane Library ClinicalTrials.gov conducted June July 2023 identify relevant randomized control (RCTs). consisted 9 which analysed data from total 623 participants. most targeted clinical was alcohol (3/9; 33.3%), followed by tobacco (2/9; 22.2%) multiple substances 22.2%). Meta‐analysis, analyses leave‐one‐out treatment effect on adverse events (AEs). Risk assessments, Egger's tests funnel plot bias. did not significantly outperform placebo (SMD = 0.189, 95% CI −0.015–0.393). Heterogeneity very high (99.26%), indicating that findings been influenced or methodological differences study protocols. Additionally, results indicate there be present. Overall, our are contrary those meta‐analyses, suggesting limited impact craving. However, heterogeneity presence identified warrants cautious interpretation meta‐analytic outcomes.

Language: Английский

Citations

1
N-acetylcysteine as a treatment for substance use cravings: A meta-analysis DOI Creative Commons
Emma L. Winterlind, Samantha G. Malone, Michael Setzer

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 13, 2024

N-acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and craving in individuals with disorders (SUDs), possibly through its potential to regulate glutamate. Though prior meta-analyses generally support NAC's efficacy reducing symptoms of craving, individual trials have found mixed results. The aims the this updated meta-analysis were (1) examine NAC treating SUD (2) explore subgroup differences, risk bias, publication bias across trials. Database searches PubMed, Cochrane Library, ClinicalTrials.gov conducted June July 2023 identify relevant randomized control (RCTs). consisted 9 which analyzed data from total 623 participants. most targeted clinical was alcohol (3/9; 33.3%), followed by tobacco (2/9; 22.2%) multiple substances 22.2%). Meta-analysis, analyses, leave-one-out analyses treatment effect on adverse events (AEs). Risk assessments, Egger's tests, funnel plot tests bias. did not significantly outperform placebo (SMD = 0.189, 95% CI -0.015 - 0.393). Heterogeneity very high (99.26%), indicating that findings been influenced or methodological differences study protocols. Additionally, results indicate there be present. Overall, our are contrary those meta-analyses, suggesting limited impact craving. However, heterogeneity presence identified warrants cautious interpretation meta-analytic outcomes.

Language: Английский

Citations

0